Magnetic nanoparticles for precision oncology: Theranostic magnetic iron oxide nanoparticles for image-guided and targeted cancer therapy

Nanomedicine

Volumn 12, Issue 1, 2017, Pages 73-87

  Zhu, Lei ^a   Zhou, Zhiyang ^a,b   Mao, Hui ^a   Yang, Lily ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Central South University   (China)

Author keywords

iron oxide nanoparticle; magnetic nanoparticles; theranostic

Indexed keywords

ANTINEOPLASTIC AGENT; FERUCARBOTRAN; FERUMOXSIL; FERUMOXYTOL; MAGNETIC IRON OXIDE NANOPARTICLE; MAGNETIC NANOPARTICLE; NANOTHERM; SMALL INTERFERING RNA; SUPERPARAMAGNETIC IRON OXIDE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; CONTRAST MEDIUM; FERRIC ION; FERRIC OXIDE; MAGNETITE NANOPARTICLE;

CANCER DIAGNOSIS; DIAGNOSTIC IMAGING; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG SAFETY; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PERSONALIZED MEDICINE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; SURFACE PROPERTY; THERANOSTIC NANOMEDICINE; THERMOTHERAPY; ANIMAL; CHEMISTRY; NEOPLASMS; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; CONTRAST MEDIA; DRUG DELIVERY SYSTEMS; FERRIC COMPOUNDS; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; NEOPLASMS; PRECISION MEDICINE; SURFACE PROPERTIES; THERANOSTIC NANOMEDICINE;

EID: 85003020586     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm-2016-0316     Document Type: Review

References (121)

1. Anand P, Kunnumakara AB, Sundaram C et al. Cancer is a preventable disease that requires major lifestyle changes. Pharm. Res. Dord. 25(9), 2097-2116 (2008).
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J. Clin. 65(1), 5-29 (2015).
3. Johnson L, Gunasekera A, Douek M. Applications of nanotechnology in cancer. Discov. Med. 47, 374-379 (2010).
4. Buzea C, Pacheco II, Robbie K. Nanomaterials and nanoparticles: sources and toxicity. Biointerphases 2(4), Mr17-Mr71 (2007).
5. Xie L, Wang G, Zhou H et al. Functional long-circulating single-walled carbon nanotubes for fluorescent/photoacoustic imaging-guided enhanced phototherapy. Biomaterials 103, 219-228 (2016).
6. Zhang LW, Gao S, Zhang F, Yang K, Ma QJ, Zhu L. Activatable hyaluronic acid nanoparticle as a theranostic agent for optical/photoacoustic image-guided photothermal therapy. ACS Nano 8(12), 12250-12258 (2014).
7. Xie J, Lee S, Chen XY. Nanoparticle-based theranostic agents. Adv. Drug Deliv. Rev. 62(11), 1064-1079 (2010).
8. Gao S, Zhang LW, Wang GH et al. Hybrid graphene/Au activatable theranostic agent for multimodalities imaging guided enhanced photothermal therapy. Biomaterials 79, 36-45 (2016).
9. Puri A, Loomis K, Smith B et al. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit. Rev. Ther. Drug 26(6), 523-580 (2009).
10. Perez-Herrero E, Fernandez-Medarde A. Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur. J. Pharm. Biopharm. 93, 52-79 (2015).
11. Zhou H, Fan Z, Deng J et al. Hyaluronidase embedded in nanocarrier PEG shell for enhanced tumor penetration and highly efficient antitumor efficacy. Nano. Lett. 16(5), 3268-3277 (2016).
12. Fu G, Zhu L, Yang K, Zhuang R, Xie J, Zhang F. Diffusionweighted magnetic resonance imaging for therapy response monitoring and early treatment prediction of photothermal therapy. ACS Appl. Mater. Interfaces 8(8), 5137-5147 (2016).
13. Makino A, Kimura S. Solid tumor-targeting theranostic polymer nanoparticle in nuclear medicinal fields. Scientific World J. 2014, 424513 (2014).
14. Huang J, Li YC, Orza A et al. Magnetic nanoparticle facilitated drug delivery for cancer therapy with targeted and image-guided approaches. Adv. Funct. Mater. 26(22), 3818-3836 (2016).
15. Laurent S, Forge D, Port M et al. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem. Rev. 108(6), 2064-2110 (2008).
16. Laurent S, Boutry S, Mahieu I, Vander Elst L, Muller RN. Iron oxide based MR contrast agents: from chemistry to cell labeling. Curr. Med. Chem. 16(35), 4712-4727 (2009).
17. Boni A, Marinone M, Innocenti C et al. Magnetic and relaxometric properties of Mn ferrites. J. Phys. D Appl. Phys. 41(13), 134021 (2008).
18. Huang J, Wang LY, Zhong XD, Li YC, Yang LL, Mao H. Facile non-hydrothermal synthesis of oligosaccharide coated sub-5 nm magnetic iron oxide nanoparticles with dual MRI contrast enhancement effects. J. Mater. Chem. B 2(33), 5344-5351 (2014).
19. Li YC, Lin R, Wang LY et al. PEG-b-AGE polymer coated magnetic nanoparticle probes with facile functionalization and anti-fouling properties for reducing non-specific uptake and improving biomarker targeting. J. Mater. Chem. B 3(17), 3591-3603 (2015).
20. Toy R, Peiris PM, Ghaghada KB, Karathanasis E. Shaping cancer nanomedicine: the effect of particle shape on the in vivo journey of nanoparticles. Nanomedicine 9(1), 121-134 (2014).
21. Liu Y, Tan J, Thomas A, Ou-Yang D, Muzykantov VR. The shape of things to come: importance of design in nanotechnology for drug delivery. Ther. Deliv. 3(2), 181-194 (2012).
22. Aslan B, Ozpolat B, Sood AK, Lopez-Berestein G. Nanotechnology in cancer therapy. J. Drug Target 21(10), 904-913 (2013).
23. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer-chemotherapy-mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46(12), 6387-6392 (1986).
24. Markman JL, Rekechenetskiy A, Holler E, Ljubimova JY. Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv. Drug Deliv. Rev. 65(14), 1866-1879 (2013).
25. Wolfbeis OS. An overview of nanoparticles commonly used in fluorescent bioimaging. Chem. Soc. Rev. 44(14), 4743-4768 (2015).
26. Petros RA, Desimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug. Discov. 9(8), 615-627 (2010).
27. Stockhofe K, Postema JM, Schieferstein H, Ross TL. Radiolabeling of nanoparticles and polymers for PET imaging. Pharmaceuticals (Basel) 7(4), 392-418 (2014).
28. Bonnemain B. Superparamagnetic agents in magnetic resonance imaging: physicochemical characteristics and clinical applications. A review. J. Drug Target 6(3), 167-174 (1998).
29. Yu MK, Park J, Jon S. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics 2(1), 3-44 (2012).
30. Chen HW, Wang LY, Yu QQ et al. Anti-HER2 antibody and ScFvEGFR-conjugated antifouling magnetic iron oxide nanoparticles for targeting and magnetic resonance imaging of breast cancer. Int. J. Nanomed. 8, 3781-3794 (2013).
31. Wang C, Sun XQ, Cheng L et al. Multifunctional theranostic red blood cells for magnetic-field-enhanced in vivo combination therapy of cancer. Adv. Mater. 26(28), 4794-+ (2014).
32. Nandwana V, De M, Chu S et al. Theranostic magnetic nanostructures (MNS) for cancer. Cancer Treat. Res. 166, 51-83 (2015).
33. Muthiah M, Park IK, Cho CS. Surface modification of iron oxide nanoparticles by biocompatible polymers for tissue imaging and targeting. Biotechnol. Adv. 31(8), 1224-1236 (2013).
34. Issa B, Obaidat IM, Albiss BA, Haik Y. Magnetic nanoparticles: surface effects and properties related to biomedicine applications. Int. J. Mol. Sci. 14(11), 21266-21305 (2013).
35. Wahajuddin, Arora S. Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers. Int. J. Nanomedicine 7, 3445-3471 (2012).
36. Albanese A, Tang PS, Chan WC. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu. Rev. Biomed. Eng. 14, 1-16 (2012).
37. Toy R, Peiris PM, Ghaghada KB, Karathanasis E. Shaping cancer nanomedicine: the effect of particle shape on the in vivo journey of nanoparticles. Nanomedicine (Lond) 9(1), 121-134 (2014).
38. Duan XP, Li YP. Physicochemical characteristics of nanoparticles affect circulation, biodistribution, cellular internalization, and trafficking. Small 9(9-10), 1521-1532 (2013).
39. Herd H, Daum N, Jones AT, Huwer H, Ghandehari H, Lehr CM. Nanoparticle geometry and surface orientation influence mode of cellular uptake. ACS Nano 7(3), 1961-1973 (2013).
40. Issa B, Obaidat IM, Albiss BA, Haik Y. Magnetic nanoparticles: surface effects and properties related to biomedicine applications. Int. J. Mol. Sci. 14(11), 21266-21305 (2013).
41. Xie J, Chen K, Lee HY et al. Ultrasmall c(RGDyK)-coated Fe3O4 nanoparticles and their specific targeting to integrin alpha(v)beta3-rich tumor cells. J. Am. Chem. Soc. 130(24), 7542-7543 (2008).
42. Sun SH, Zeng H. Size-controlled synthesis of magnetite nanoparticles. J. Am. Chem. Soc. 124(28), 8204-8205 (2002).
43. Wang LN, Tang W, Zhen ZP, Chen HM, Xie J, Zhao Q. Improving detection specificity of iron oxide nanoparticles (IONPs) using the SWIFT sequence with long T-2 suppression. Magn. Reson. Imaging 32(6), 671-678 (2014).
44. Schleich N, Po C, Jacobs D et al. Comparison of active, passive and magnetic targeting to tumors of multifunctional paclitaxel/SPIO-loaded nanoparticles for tumor imaging and therapy. J. Control. Release 194, 82-91 (2014).
45. Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7(9), 771-782 (2008).
46. Yang L, Kuang HJ, Zhang WY et al. Size dependent biodistribution and toxicokinetics of iron oxide magnetic nanoparticles in mice. Nanoscale 7(2), 625-636 (2015).
47. Park JH, Von Maltzahn G, Zhang LL et al. Magnetic iron oxide nanoworms for tumor targeting and imaging. Adv. Mater. 20(9), 1630-+ (2008).
48. Veiseh O, Gunn JW, Zhang MQ. Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv. Drug Deliv. Rev. 62(3), 284-304 (2010).
49. Liu Z, Cai W, He L et al. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat. Nanotechnol. 2(1), 47-52 (2007).
50. Kolhatkar AG, Jamison AC, Litvinov D, Willson RC, Lee TR. Tuning the magnetic properties of nanoparticles. Int. J. Mol. Sci. 14(8), 15977-16009 (2013).
51. Guardia P, Labarta A, Batlle X. Tuning the size, the shape, and the magnetic properties of iron oxide nanoparticles. J. Phys. Chem. C 115(2), 390-396 (2011).
52. Kolhatkar AG, Jamison AC, Litvinov D, Willson RC, Lee TR. Tuning the magnetic properties of nanoparticles. Int. J. Mol. Sci. 14(8), 15977-16009 (2013).
53. Huang J, Zhong X, Wang L, Yang L, Mao H. Improving the magnetic resonance imaging contrast and detection methods with engineered magnetic nanoparticles. Theranostics 2(1), 86-102 (2012).
54. Bjornerud A, Johansson L. The utility of superparamagnetic contrast agents in MRI: theoretical consideration and applications in the cardiovascular system. NMR Biomed. 17(7), 465-477 (2004).
55. Wang LY, Zhong XD, Qian WP et al. Ultrashort echo time (UTE) imaging of receptor targeted magnetic iron oxide nanoparticles in mouse tumor models. J. Magn. Reson. Imaging 40(5), 1071-1081 (2014).
56. Jia K, Zhang JD, Huang X, Liu XB. Size dependent electromagnetic properties of Fe3O4 nanospheres. Chem. Phys. Lett. 614, 31-35 (2014).
57. Zhang W. Nanoparticle aggregation: principles and modeling. Adv. Exp. Med. Biol. 811, 19-43 (2014).
58. Bullivant JP, Zhao S, Willenberg BJ, Kozissnik B, Batich CD, Dobson J. Materials characterization of feraheme/ferumoxytol and preliminary evaluation of its potential for magnetic fluid hyperthermia. Int. J. Mol. Sci. 14(9), 17501-17510 (2013).
59. Kievit FM, Veiseh O, Bhattarai N et al. PEI-PEG-chitosancopolymer-coated iron oxide nanoparticles for safe gene delivery: synthesis, complexation, and transfection. Adv. Funct. Mater. 19(14), 2244-2251 (2009).
60. Yang LL, Peng XH, Wang YA et al. Receptor-targeted nanoparticles for in vivo imaging of breast cancer. Clin. Cancer Res. 15(14), 4722-4732 (2009).
61. Xie J, Wang JH, Niu G et al. Human serum albumin coated iron oxide nanoparticles for efficient cell labeling. Chem. Commun. 46(3), 433-435 (2010).
62. Lee H, Lee E, Kim DK, Jang NK, Jeong YY, Jon S. Antibiofouling polymer-coated superparamagnetic iron oxide nanoparticles as potential magnetic resonance contrast agents for in vivo cancer imaging. J. Am. Chem. Soc. 128(22), 7383-7389 (2006).
63. Moore A, Marecos E, Bogdanov A, Weissleder R. Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model. Radiology 214(2), 568-574 (2000).
64. Harisinghani MG, Barentsz J, Hahn PF et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N. Engl. J. Med. 348(25), U2491-U2495 (2003).
65. Schultz JF, Bell JD, Goldstein RM, Kuhn JA, Mccarty TM. Hepatic tumor imaging using iron oxide MRI: comparison with computed tomography, clinical impact, and cost analysis. Ann. Surg. Oncol. 6(7), 691-698 (1999).
66. Mouli SK, Zhao LC, Omary RA, Thaxton CS. Lymphotropic nanoparticle enhanced MRI for the staging of genitourinary tumors. Nat. Rev. Urol. 7(2), 84-93 (2010).
67. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol. 33(9), 941-951 (2015).
68. Park SJ, Lee KB, Choi IS, Langer R, Jon SY. Dual functional, polymeric self-assembled monolayers as a facile platform for construction of patterns of biomolecules. Langmuir 23(22), 10902-10905 (2007).
69. Chen HW, Wang LY, Yeh J et al. Reducing non-specific binding and uptake of nanoparticles and improving cell targeting with an antifouling PEO-b-P gamma MPS copolymer coating. Biomaterials 31(20), 5397-5407 (2010).
70. Weissleder R, Stark DD, Engelstad BL et al. Superparamagnetic iron-oxide-pharmacokinetics and toxicity. Am. J. Roentgenol. 152(1), 167-173 (1989).
71. Mahmoudi M, Laurent S, Shokrgozar MA, Hosseinkhani M. Toxicity evaluations of superparamagnetic iron oxide nanoparticles: cell 'vision' versus physicochemical properties of nanoparticles. ACS Nano 5(9), 7263-7276 (2011).
72. Liu G, Gao J, Ai H, Chen X. Applications and potential toxicity of magnetic iron oxide nanoparticles. Small 9(9-10), 1533-1545 (2013).
73. Di Bona KR, Xu YL, Ramirez PA et al. Surface charge and dosage dependent potential developmental toxicity and biodistribution of iron oxide nanoparticles in pregnant CD-1 mice. Reprod. Toxicol. 50, 36-42 (2014).
74. Chen YS, Gong L, Gao N et al. Preclinical evaluation of a urokinase plasminogen activator receptor-targeted nanoprobe in rhesus monkeys. Int. J. Nanomed. 10, 6689-6698 (2015).
75. Schwenk MH. Ferumoxytol: a new intravenous iron preparation for the treatment of iron deficiency anemia in patients with chronic kidney disease. Pharmacotherapy 30(1), 70-79 (2010).
76. Hetzel D, Strauss W, Bernard K, Li Z, Urboniene A, Allen LF. A Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy. Am. J. Hematol. 89(6), 646-650 (2014).
77. Harisinghani M, Ross RW, Guimaraes AR, Weissleder R. Utility of a new bolus-injectable nanoparticle for clinical cancer staging. Neoplasia 9(12), 1160-1165 (2007).
78. European Medicines Agency (EMA). Superparamagnetic iron oxide nanoparticles stabilised with dextran and sodium citrate. Doc. Ref.: EMEA/CHMP/11527/2008 Procedure No. EMEA/H/C/801, 10-12 (2008). www.ema.europa.eu
79. Pankhurst QA, Thanh NTK, Jones SK, Dobson J. Progress in applications of magnetic nanoparticles in biomedicine. J. Phys. D Appl. Phys. 42(22), 224001 (2009).
80. Choi KY, Liu G, Lee S, Chen XY. Theranostic nanoplatforms for simultaneous cancer imaging and therapy: current approaches and future perspectives. Nanoscale 4(2), 330-342 (2012).
81. Schleich N, Sibret P, Danhier P et al. Dual anticancer drug/superparamagnetic iron oxide-loaded PLGA-based nanoparticles for cancer therapy and magnetic resonance imaging. Int. J. Pharmaceut. 447(1-2), 94-101 (2013).
82. Choi KY, Yoon HY, Kim JH et al. Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy. ACS Nano 5(11), 8591-8599 (2011).
83. Zuckerman JE, Gritli I, Tolcher A et al. Correlating animal and human Phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. Proc. Natl Acad. Sci. USA 111(31), 11449-11454 (2014).
84. Xing R, Bhirde AA, Wang S et al. Hollow iron oxide nanoparticles as multidrug resistant drug delivery and imaging vehicles. Nano Res. 6(1), 1-9 (2012).
85. Wagstaff AJ, Brown SD, Holden MR et al. Cisplatin drug delivery using gold-coated iron oxide nanoparticles for enhanced tumour targeting with external magnetic fields. Inorganica Chimica Acta 393, 328-333 (2012).
86. Zhou Z, Sun Y, Shen J et al. Iron/iron oxide core/shell nanoparticles for magnetic targeting MRI and near-infrared photothermal therapy. Biomaterials 35(26), 7470-7478 (2014).
87. Wang DS, Fei BW, Halig LV et al. Targeted iron-oxide nanoparticle for photodynamic therapy and imaging of head and neck cancer. ACS Nano 8(7), 6620-6632 (2014).
88. Zhang F, Huang XL, Zhu L et al. Noninvasive monitoring of orthotopic glioblastoma therapy response using RGDconjugated iron oxide nanoparticles. Biomaterials 33(21), 5414-5422 (2012).
89. Wang GH, Zhang F, Tian R et al. Nanotubes-embedded indocyanine green-hyaluronic acid nanoparticles for photoacoustic-imaging-guided phototherapy. ACS Appl. Mater. Inter. 8(8), 5608-5617 (2016).
90. Tse BW, Cowin GJ, Soekmadji C et al. PSMA-targeting iron oxide magnetic nanoparticles enhance MRI of preclinical prostate cancer. Nanomedicine (Lond) 10(3), 375-386 (2015).
91. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv. Drug Deliver. Rev. 60(15), 1615-1626 (2008).
92. Zhou HY, Qian WP, Uckun FM et al. IGF1 receptor targeted theranostic nanoparticles for targeted and imageguided therapy of pancreatic cancer. ACS Nano 9(8), 7976-7991 (2015).
93. Lee GY, Qian WP, Wang LY et al. Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer. ACS Nano 7(3), 2078-2089 (2013).
94. Arosio P, Orsini F, Piras AM et al. MR imaging and targeting of human breast cancer cells with folate decorated nanoparticles. RSC Adv. 5(50), 39760-39770 (2015).
95. Peng XH, Qian XM, Mao H et al. Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. Int. J. Nanomed. 3(3), 311-321 (2008).
96. Ling D, Park W, Park SJ et al. Multifunctional tumor pHsensitive self-assembled nanoparticles for bimodal imaging and treatment of resistant heterogeneous tumors. J. Am. Chem. Soc. 136(15), 5647-5655 (2014).
97. Xie J, Zhang F, Aronova M et al. Manipulating the power of an additional phase: a flower-like Au-Fe3O4 optical nanosensor for imaging protease expressions in vivo. ACS Nano 5(4), 3043-3051 (2011).
98. Mccarthy JR, Weissleder R. Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv. Drug Deliv. Rev. 60(11), 1241-1251 (2008).
99. Quan QM, Xie J, Gao HK et al. HSA coated iron oxide nanoparticles as drug delivery vehicles for cancer therapy. Mol. Pharmaceut. 8(5), 1669-1676 (2011).
100. Aires A, Ocampo SM, Simoes BM et al. Multifunctionalized iron oxide nanoparticles for selective drug delivery to CD44-positive cancer cells. Nanotechnology 27(6), 065103 (2016).
101. Bremnes RM, Donnem T, Al-Saad S et al. The role of tumor stroma in cancer progression and prognosis emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J. Thorac. Oncol. 6(1), 209-217 (2011).
102. Lartigue L, Innocenti C, Kalaivani T et al. Water-dispersible sugar-coated iron oxide nanoparticles. an evaluation of their relaxometric and magnetic hyperthermia properties. J. Am. Chem. Soc. 133(27), 10459-10472 (2011).
103. Torres-Lugo M, Rinaldi C. Thermal potentiation of chemotherapy by magnetic nanoparticles. Nanomedicine (Lond.) 8(10), 1689-1707 (2013).
104. Hilger I. In vivo applications of magnetic nanoparticle hyperthermia. Int. J. Hyperthermia 29(8), 828-834 (2013).
105. Hilger I, Kaiser WA. Iron oxide-based nanostructures for MRI and magnetic hyperthermia. Nanomedicine (Lond.) 7(9), 1443-1459 (2012).
106. Zhao Q, Wang L, Cheng R et al. Magnetic nanoparticlebased hyperthermia for head & neck cancer in mouse models. Theranostics 2, 113-121 (2012).
107. Maier-Hauff K, Ulrich F, Nestler D et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J. Neurooncol. 103(2), 317-324 (2011).
108. Medarova Z, Pham W, Farrar C, Petkova V, Moore A. In vivo imaging of siRNA delivery and silencing in tumors. Nat. Med. 13(3), 372-377 (2007).
109. Sun ZC, Song XX, Li XJ et al. In vivo multimodality imaging of miRNA-16 iron nanoparticle reversing drug resistance to chemotherapy in a mouse gastric cancer model. Nanoscale 6(23), 14343-14353 (2014).
110. Mahajan UM, Teller S, Sendler M et al. Tumour-specific delivery of siRNA-coupled superparamagnetic iron oxide nanoparticles, targeted against PLK1, stops progression of pancreatic cancer. Gut doi:10.1136/gutjnl-2016-311393 (2016) (Epub ahead of print).
111. Wen G, Zhang XL, Chang RM, Xia Q, Cang P, Zhang Y. Superparamagnetic iron oxide (Feridex)-enhanced MRI in diagnosis of focal hepatic lesions. Di Yi Jun Yi Da Xue Xue Bao 22(5), 451-452 (2002).
112. Clement O, Siauve N, Cuenod CA, Frija G. Liver imaging with ferumoxides (Feridex): fundamentals, controversies, and practical aspects. Top. Magn. Reson. Imaging 9(3), 167-182 (1998).
113. Johnson L, Pinder SE, Douek M. Deposition of superparamagnetic iron-oxide nanoparticles in axillary sentinel lymph nodes following subcutaneous injection. Histopathology 62(3), 481-486 (2013).
114. Kernstine KH, Stanford W, Mullan BF et al. PET, CT, and MRI with Combidex for mediastinal staging in non-small cell lung carcinoma. Ann. Thorac. Surg. 68(3), 1022-1028 (1999).
115. Harisinghani MG, Saini S, Hahn PF, Weissleder R, Mueller PR. MR imaging of lymph nodes in patients with primary abdominal and pelvic malignancies using ultrasmall superparamagnetic iron oxide (Combidex). Acad. Radiol. 5(Suppl. 1), S167-S169 (1998).
116. Reimer P, Balzer T. Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrastenhanced MRI of the liver: properties, clinical development, and applications. Eur. Radiol. 13(6), 1266-1276 (2003).
117. Vogl TJ, Hammerstingl R, Schwarz W et al. Magnetic resonance imaging of focal liver lesions. Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient. Invest. Radiol. 31(11), 696-708 (1996).
118. Reimer P, Rummeny EJ, Daldrup HE et al. Clinical results with Resovist: a Phase 2 clinical trial. Radiology 195(2), 489-496 (1995).
119. Campbell JL, Arora J, Cowell SF et al. Quasi-cubic magnetite/silica core-shell nanoparticles as enhanced MRI contrast agents for cancer imaging. PLoS ONE 6(7), e21857 (2011).
120. Bullivant JP, Zhao S, Willenberg BJ, Kozissnik B, Batich CD, Dobson J. Materials characterization of Feraheme/ferumoxytol and preliminary evaluation of its potential for magnetic fluid hyperthermia. Int. J. Mol. Sci. 14(9), 17501-17510 (2013).
121. Maier-Hauff K, Ulrich F, Nestler D et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J. Neuro-Oncol. 103(2), 317-324 (2011).